Abstract
With the increasing use of new tyrosine kinase inhibitors it has been suggested that the spectrum of kinase domain mutations may change and possible selection of new resistant clones may occur. We describe a Ph + chronic myeloid leukaemia (CML) patient with primary resistance to imatinib who received without success sequential therapy with multiple TKIs, and developed sequential emergence of kinase domain mutations after these treatments.
This is a preview of subscription content, log in via an institution to check access.
References
Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five year follow up of patients receiving imatinib for chronic myeloid leukaemia. New Engl J Med 355:2408–2417
Apperley JF (2007) Mechanisms of resistance to imatinib in chronic myeloid leukaemia (part I and II). Lancet Oncol 8:1018–1029
Hochhaus A, Erben P, Ernst T et al (2007) Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol 44(suppl 1):S15–S24
Kantarjian H, Giles F, Quintas-Cardama A, Cortes J (2007) Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13:1089–1097
Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O’Brien S et al (2007) Dynamics of BCR–ABL kinase domain mutations in chronic myeloid leukaemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110:4005–4011
Jabbour E, Kantarjian H, Jones D et al (2006) Frequency and clinical significance of BCR–ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20:1767–1773
Branford S, Rudzki Z, Walsh S et al (2003) Detection of BCR–ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (p-loop) are associated with a poor prognosis. Blood 102:276–283
Khorashad JS, de Lavallade H, Apperley J, Miloikovic D, Reid AG, Bua M et al (2008) Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26:4806–4813
O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MWN, Druker BJ (2005) In vitro activity of BCR–ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500–4505
Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I (2006) Presence or emergence of a F317L BCR–ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 24:e51–e52
Bradeen HA, Eide CA, O’Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW (2006) Comparison of imatinib mesylate, dasatinib, and nilotinib in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108:2332–2338
Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL et al (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR–ABL mutations with altered oncogenic potency. J Clin Invest 177:2562–2569
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Breccia, M., Frustaci, A.M., Cannella, L. et al. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?. Cancer Chemother Pharmacol 64, 195–197 (2009). https://doi.org/10.1007/s00280-008-0905-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-008-0905-5